Associated Papers
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
Bazhenova L et al.
Clinical Lung Cancer, 2025
Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases.
Usui Y et al.
Blood Cancer Discovery, 2025
Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples.
Paweletz CP et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Clinical Validation of Local Versus Commercial Genomic Testing in Cancer: A Comparison of Tissue and Plasma Concordance.
Faulkner LG et al.
Cancer Investigation, 2025
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.
Yaeger R et al.
Cancer Discovery, 2024
Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma.
Khalil SS et al.
Cureus, 2024
Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population.
Rosenberg S et al.
Molecular Oncology, 2023
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials.
Ishikawa T et al.
Iscience, 2023
Next-generation sequencing redefines the diagnosis of triple-negative myeloproliferative neoplasms.
Wu S et al.
Annals of Hematology, 2022
TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin.
Hinz TK et al.
Molecular Pharmacology, 2021
Comprehensive molecular profiling of pulmonary pleomorphic carcinoma.
Nagano M et al.
Npj Precision Oncology, 2021
Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants.
Inagaki-Kawata Y et al.
Communications Biology, 2020
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Li K et al.
Breast Cancer Research and Treatment, 2020
Identification of relevant genetic alterations in cancer using topological data analysis.
Rabadán R et al.
Nature Communications, 2020
A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations.
Demuth C et al.
Oncotarget, 2018
Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.
Plagnol V et al.
Plos One, 2018
Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.
Aldoss I et al.
Haematologica, 2017
HPV-negative penile squamous cell carcinoma: disruptive mutations in the TP53 gene are common.
Kashofer K et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2017
Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM et al.
International Journal of Cancer, 2016
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
Witkiewicz AK et al.
Nature Communications, 2015